Glabridin inhibits cancer stem cell formation via the TGF-β/SMAD2 pathway in breast and liver cancers, and epithelial–mesenchymal transition through upregulation of E-cadherin and cancer cell migration and invasion by blocking FAK/Src activation in breast and lung cancers [37]. Here, CDH1 is linked to lung carcinoma.